Vertex Pharmaceuticals stock falls after pain drug fails in Phase 2 study
John P. Babcock, the Senior Executive Vice President and President of Private Wealth Management at Peapack Gladstone Financial Corp (NASDAQ:PGC), recently sold 10,000 shares of the company’s common stock. The transaction, which took place on March 19, 2025, was executed at a price of $28.7646 per share, totaling $287,646. According to InvestingPro analysis, PGC currently appears slightly undervalued, with the stock showing a strong 23% return over the past year despite recent market volatility.
Following this sale, Babcock holds 39,155 shares directly. He also maintains indirect ownership of additional shares through a rabbi trust and a 401(k) plan, with 47,925 shares and 6,673.71 shares, respectively. Additionally, Babcock’s holdings include various restricted stock units and phantom stock, which are subject to vesting conditions and performance criteria. The company has maintained dividend payments for 28 consecutive years, demonstrating strong financial stability. InvestingPro subscribers can access 5 additional key insights about PGC’s financial health and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.